{
BioNTech SE

Companies

}
Symbol BNTX
Name BioNTech SE
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country Germany
State
City Mainz
Zipcode 55131
Website http://www.biontech.de
Track all markets on TradingView
biontech expands oncology focus with biotheus acquisition and promising pipeline
In 2024, BioNTech is set to enhance its oncology focus with the acquisition of Biotheus, expanding its bispecific antibody expertise and production capacity. The company reported strong Q3 results with EUR 1.2 billion in sales, driven by COVID-19 vaccines, while long-term growth hinges on its oncology pipeline, which includes over 32 clinical trials. Meanwhile, Evotec and Vidac Pharma are also making strides in cancer research, with Evotec emphasizing innovative partnerships and Vidac securing a key patent for its unique cancer therapies.
kapitalerhoehungen.de
Euro United States Dollar BioNTech SE DEU USA CHN Helen Torley Show more
Healthcare, Market Report
06:00 02.12.2024
Evercore ISI upgrades BioNTech amid RFK Jr nomination chaos
Evercore ISI has upgraded BioNTech, citing the "chaos" surrounding RFK Jr."s nomination as a potential buying opportunity for investors. This strategic move reflects confidence in BioNTech"s prospects amid the current political landscape.
CNBC
BioNTech SE DEU
Healthcare, Market Report
13:38 19.11.2024
political turmoil impacts bio pharmaceutical stocks with long term potential
Shares of BioNTech, Moderna, and Pfizer are under pressure following Donald Trump's announcement to appoint anti-vaccine advocate Robert F. Kennedy Jr. as Secretary of Health and Human Services, raising concerns over increased regulation and reduced government support.Despite short-term turbulence, BioNTech's acquisition of Biotheus and ongoing cancer research projects signal long-term potential. Pfizer is also focusing on gene therapy and oncology, presenting opportunities for investors willing to navigate the current volatility.
finanznachrichten.de
United States Dollar Euro BioNTech SE Pfizer Inc. USA Donald Trump Robert F. Kennedy Jr.
Healthcare, Market Report
10:46 18.11.2024
trump appoints robert f kennedy jr as health secretary raising concerns
Donald Trump has appointed Robert F. Kennedy Jr., a prominent vaccine skeptic, as Secretary of Health, raising concerns within the scientific community. Kennedy, who previously ran as an independent, has made controversial claims about vaccines and the FDA, leading to significant stock declines for major pharmaceutical companies. His views on public health and regulatory practices could challenge the pharmaceutical industry's influence over health policies.
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco
Euro United States Dollar Moderna, Inc. BioNTech SE Pfizer Inc. GSK plc USA DEU Donald Trump Jeremy Levin Anthony Fauci Bill Gates Robert Kennedy Jr Show more
Regulatory & Legal, News Article
05:52 16.11.2024
healthcare sector reacts negatively to robert f kennedy jr appointment
Robert F. Kennedy Jr.'s appointment as Health Minister in Donald Trump's administration has triggered a significant decline in pharmaceutical stocks across the US and Europe, with fears of potential drug price caps impacting investor confidence. Major companies like UCB and argenx saw sharp drops, reflecting broader concerns about the future of drug pricing and regulation under Kennedy's leadership. Analysts suggest that while there are constraints on his power, the potential for reduced regulations could lead to increased mergers and acquisitions in the sector.
L'Echo
United States Dollar Moderna, Inc. BioNTech SE Pfizer Inc. Genmab A/S Novavax, Inc. UCB SA AstraZeneca PLC Sanofi GSK plc USA CHE BEL Robert F. Kennedy Jr. Donald Trump Ashish Jha James Capretta Chris Meekins Show more
Finance & Economy, Market Report
15:24 15.11.2024
vaccine maker stocks decline after trump nominates rfk jr for hhs
Shares of vaccine manufacturers plummeted following President-elect Donald Trump's nomination of Robert F. Kennedy Jr., a noted vaccine skeptic, to lead the Department of Health and Human Services. Moderna, Novavax, Pfizer, and BioNTech all experienced significant declines, with Moderna down over 5% and Novavax falling more than 7%. Experts warn that Kennedy's influence could amplify anti-vaccine sentiments, potentially hindering vaccination efforts in the U.S.
CNBC
Euro United States Dollar Moderna, Inc. Novavax, Inc. GSK plc BioNTech SE Pfizer Inc. USA DEU Robert F. Kennedy Jr. Donald Trump Show more
Regulatory & Legal, Market Report
22:12 14.11.2024
merck invests in new cancer immunotherapy to counter keytruda competition
Merck & Co. has acquired worldwide rights to LaNova Medicines' cancer therapy LM-299 for $588 million, a bispecific immunotherapy targeting PD-1 and VEGF, currently in Phase 1 testing. This move comes as a response to increasing competition, particularly after ivonescimab outperformed Keytruda in a lung cancer trial. The deal could yield LaNova up to $2.7 billion based on development milestones, highlighting Merck's strategy to bolster its pipeline ahead of Keytruda's patent expiration in 2028.
BioPharma Dive
United States Dollar LaNova Medicines Merck & Co., Inc. Summit Therapeutics plc Biotheus Eisai Co., Ltd. BioNTech SE Akeso, Inc. USA CHN Umer Raffat Dean Li Show more
Healthcare, Market Report
01:00 14.11.2024
us investigates ubS over russian client accounts following cs acquisition
UBS is under investigation by US authorities regarding Russian clients inherited from its acquisition of Credit Suisse. The Office of Foreign Assets Control (OFAC) is scrutinizing these accounts, prompting UBS to segregate suspicious funds and close certain accounts to mitigate potential repercussions. While UBS is cooperating, the extent of problematic Russian funds remains unclear, as the bank sheds unwanted clients linked to Russia.
investrends.ch
British Pound Sterling United States Dollar PostFinance AG Biotheus UBS AG BioNTech SE SIX BBS AG Commonwealth Bank of Australia Liechtenstein Academy Foundation Credit Suisse Anlagestiftung USA RUS CHN AUS CHE DEU Show more
TradFi, Press Release
08:19 13.11.2024
BioNTech reports strong earnings driven by Covid-19 vaccine sales
BioNTech reported strong quarterly results, driven by robust sales of its variant-adapted Covid-19 vaccines. The company achieved earnings per diluted share of €0.81 ($0.88) in the third quarter, significantly surpassing analysts' expectations of a loss of €1.84.
bloomberg.com
Euro BioNTech SE DEU
Finance & Economy, Market Report
12:50 04.11.2024
european startup exits decline amid fragmented market and lack of tech giants
The European startup M&A market has contracted significantly, with only five billion-dollar deals in 2023, none involving venture capital-backed companies. The absence of major tech giants limits high-profile exits, leading to lower valuations and a fragmented ecosystem compared to the U.S., where large companies drive innovation and acquisitions. This disparity highlights the challenges faced by European startups in achieving growth and attracting investment.
Agenda Digitale
United States Dollar British Pound Sterling Euro Deutsche Börse AG Amazon.com, Inc. Oracle Corporation Google Inc. SAP SE Aqua Metals, Inc. BioNTech SE Microsoft Corporation Deutsche Börse's acquisition of SimCorp BioNTech's acquisition of InstaDeep Show more
Finance & Economy, Market Report
11:11 31.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.